EndoCM Salud Metabólica retweetledi
🚨Inpatient safety, effectiveness of SGLT2 inh. and GLP-1 RAs in type 2 diabetes: ENDOCARE, a pragmatic prospective cohort study 🆓🇪🇸
🏥 979, managed either on oral
antidiabetic drugs (with or without insulin) under a start–stop protocol (Group A) or with insulin-only therapy
(Group B)
📊 Group A was associated with a ⬇️ 47% risk of severe AE (level 2–3 hypoglycaemia or DKA)(aOR 0.53) and after PS matching (OR 0.31).
📉Group A had a lower median daily glucose level (153 mg/dL vs. 179 mg/dL), lower glycaemic variability and a shorter hospital stay (5 days vs. 7 days)
☠️No differences
🚩What is new?
• In hospital non-insulin glucose-lowering therapies reduce hypoglycaemia risk.
• Achieve superior glycemic control with reduced variability.
• Shorten hospital stay without increased ICU admission or mortality.
🚩How might this study influence clinical practice?
Our proof of concept suggests reevaluating standard practices for early in-hospital SGLT2i/GLP-1RA use.
👉🏻evidence supporting a transition from the traditional practice of therapeutic deferral to a more proactive inpatient management strategy
👉🏻hospitalization represents a strategic opportunity to initiate SGLT2 inh. and GLP-1RAs, moving beyond acute stabilization toward the optimization of long-term cardiometabolic care. @isabial_iis @GVAsanitat @BioMedCentral @SpringerNature @diabeteSEEN @SEDiabetes @secardiologia @SENefrologia @Sociedad_SEMI @SEMERGENap @semfyc @fjavesc @cristinatejerap @CristobMorales @DrTinahones @ketandhatariya @ADA_DiabetesPro @EASDnews @EASDelearning @TheAACE @ThaerIdrees @InzucchiSE @AnnePetersMD @EricTopol
link.springer.com/content/pdf/10…
English
